The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.
An open-source platform developed by researchers in Nikolaus Rajewsky’s lab at the Max Delbrück Center creates molecular maps from patient tissue samples with subcellular precision, enabling detailed study and potentially enhancing routine clinical…
Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting with the…
Berlin Center for Gene and Cell Therapies aspires to create a leading biotech ecosystem in Berlin / Federal Chancellor Scholz acknowledges the importance of the project for Germany / Governing Mayor of Berlin Kai Wegner assures support from the State…
Groundbreaking innovations by researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) provided the basis for the development of an antibody-drug conjugate (ADC) by the company Tubulis, which is now being used in a Phase I/IIa…
IDEA Studios will be strategically located in Asian and European innovation hubs to partner closely with early-stage companies focused on improving patient care
Whether COVID-19 is mild or severe depends not only on how aggressive the coronavirus is, but also on the immune response of the infected individual. Using single-cell analyses, Berlin researchers have now identified two distinct molecular patterns…
Today, the Berlin Institute of Health at Charité (BIH) officially handed over the National Strategy for Gene and Cell Therapies to Federal Research Minister Bettina Stark-Watzinger (FDP). Some 150 experts from various stakeholder groups drew up the…
„Berlin is the best place for AI startups in Germany”
BERLIN, Germany, June 11, 2024 – Tacalyx, a privately held biotech company focused on developing novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announces the extension of its seed financing to over €14 M. This extension…
